Baloxavir marboxil: a novel cap-dependent endonuclease (CEN)
inhibitor for the treatment of acute uncomplicated influenza

Locke, Shyanne C; Splawn, L.M.; Cho, Jonathan C.

doi:10.1358/dot.2019.55.6.2999889

Cited by 12 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A novel antiviral drug, called baloxavir marboxil, has recently been approved in Japan and the United States. 3 This drug has become commercially available in Japan in March 2018. It reduces viral proliferation through a new mechanism of action wherein it inhibits cap-dependent endonucleases.…”

Section: Introductionmentioning

confidence: 99%

<p>Clinical Efficacy of Baloxavir Marboxil in the Treatment of Seasonal Influenza in Adult Patients: A Prospective Observational Study</p>

Kitazawa

Ota

2020

IJGM

View full text Add to dashboard Cite

Baloxavir marboxil, a recently developed antiviral drug, has been used to treat influenza in some countries including Japan. The aim of this study was to determine the clinical efficacy of the drug, which currently remains unclear. Patients and Methods: Overall, 43 adult patients with seasonal influenza who visited the outpatient clinic of Teikyo University Hospital in Tokyo during the winter of 2018-2019 were enrolled. Of them, 14, 13, and 16 were prescribed baloxavir marboxil (40 or 80 mg once), oseltamivir (75 mg twice daily for 5 days), and laninamivir (40 mg once), respectively. A questionnaire was used to collect data about symptoms, and the Medical Outcome Study 8-Items Short Form Health Survey was employed to examine health-related quality-oflife (HRQOL) before and 7 days after admission. The main study endpoints included time to defervescence and the extent of improvement in HRQOL after treatment initiation. The data were analyzed with Welch's t-test and Fisher's exact test using StatFlex version 6. Results: No significant differences in clinical background characteristics were observed among the patients. The mean time to defervescence in the baloxavir group (median [interquartile range]; 1.0 [1.0-2.0] days) was significantly shorter than that in the laninamivir group (2.0 [1.5-3.5] days; p=0.0322). No significant differences in mean time to defervescence, change in HRQOL, and time for resolution of other symptoms were observed between the groups. Conclusion: The results suggest that baloxavir marboxil has a better antipyretic effect than oseltamivir and laninamivir. Moreover, baloxavir marboxil might be clinically more valuable than the other two drugs owing to higher medication adherence among patients.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Clinical Efficacy of Baloxavir Marboxil in the Treatment of Seasonal Influenza in Adult Patients: A Prospective Observational Study</p>

Kitazawa

Ota

2020

IJGM

View full text Add to dashboard Cite

show abstract

“…Baloxavir is a novel cap-dependent endonuclease inhibitor that blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis. This is in contrast to neuraminidase inhibitors, which impair viral release from infected host cells …”

Section: Anti-infective Drugsmentioning

confidence: 91%

Synthetic Approaches to New Drugs Approved during 2018

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The only drug in its class examined identified in the current review was baloxavir marboxil. This drug targets the viral polymerase acidic protein to block the endonuclease function, resulting in the inhibition of virus mRNA transcription and infection ( Koszalka et al, 2019 ; Locke et al, 2019 ). Only one small clinical study in China has been identified in the current review, but due to the small sample the implications will be limited (ChiCTR2000029548).…”

Section: Direct Antivirals Used In Covid-19mentioning

confidence: 99%

Directly Acting Antivirals for COVID-19: Where Do We Stand?

et al. 2020

View full text Add to dashboard Cite

The outbreak of a novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 has now become a pandemic with no approved therapeutic agent. At the moment, the genomic structure, characteristics, and pathogenic mechanisms of SARS-CoV-2 have been reported. Based upon this information, several drugs including the directly acting antivirals have been proposed to treat people with coronavirus disease 2019 (COVID-19). This rapid review aims to describe the directly acting antivirals that have been examined for use in the management of COVID-19. Searches were conducted in three electronic databases, supplemented with a search on arXiv, bioRxiv, medRxiv, ChinaXiv, ClinicalTrials.gov , and Chinese Clinical Trial Registry for studies examining the use of antivirals in COVID-19 to identify for case reports, case series, observational studies, and randomized controlled studies describing the use of antivirals in COVID-19. Data were extracted independently and presented narratively. A total of 98 studies were included, comprising of 38 published studies and 60 registered clinical trials. These drugs include the broad spectrum antivirals such as umifenovir, protease inhibitors such as lopinavir/ritonavir as well as the RNA-dependent RNA polymerase inhibitors, remdesivir, and favipiravir. Other drugs that have been used include the nucleosidase inhibitors and polymerase acidic endonuclease inhibitors which are currently approved for prevention of influenza infections. While some of the drugs appear promising in small case series and reports, more clinical trials currently in progress are required to provide higher quality evidence.

show abstract

Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the treatment of acute uncomplicated influenza

Cited by 12 publications

References 0 publications

<p>Clinical Efficacy of Baloxavir Marboxil in the Treatment of Seasonal Influenza in Adult Patients: A Prospective Observational Study</p>

<p>Clinical Efficacy of Baloxavir Marboxil in the Treatment of Seasonal Influenza in Adult Patients: A Prospective Observational Study</p>

Synthetic Approaches to New Drugs Approved during 2018

Directly Acting Antivirals for COVID-19: Where Do We Stand?

Contact Info

Product

Resources

About